Bill
Bill > S4152
US S4152
US S4152A bill to amend the Federal Food, Drug, and Cosmetic Act to reauthorize the Critical Path Public-Private Partnerships.
summary
Introduced
05/05/2022
05/05/2022
In Committee
05/05/2022
05/05/2022
Crossed Over
Passed
Dead
01/03/2023
01/03/2023
Introduced Session
117th Congress
Bill Summary
A BILL To amend the Federal Food, Drug, and Cosmetic Act to reauthorize the Critical Path Public-Private Partnerships.
AI Summary
This bill would reauthorize the Critical Path Public-Private Partnerships program under the Federal Food, Drug, and Cosmetic Act. The bill increases the authorized funding for the program from $6 million per year for fiscal years 2018 through 2022 to $10 million per year for fiscal years 2023 through 2027. The Critical Path Public-Private Partnerships program allows the Food and Drug Administration to collaborate with private and public entities to help accelerate the development of new medical products.
Committee Categories
Health and Social Services
Sponsors (3)
Last Action
Read twice and referred to the Committee on Health, Education, Labor, and Pensions. (on 05/05/2022)
Official Document
bill text
bill summary
Loading...
bill summary
Loading...
bill summary
| Document Type | Source Location |
|---|---|
| State Bill Page | https://www.congress.gov/bill/117th-congress/senate-bill/4152/all-info |
| BillText | https://www.congress.gov/117/bills/s4152/BILLS-117s4152is.pdf |
| Bill | https://www.congress.gov/117/bills/s4152/BILLS-117s4152is.pdf.pdf |
Loading...